Prolonged oxygen deprivation corresponding to the ischemic period is observed during liver resection, transplantation, and trauma and subsequent oxygen restoration always leads to reperfusion injury. In particular, the ischemic period represents an inevitable event during conventional organ preservation before transplantation and the magnitude and severity of reperfusion injury depend on the time of liver preservation. Faced with the increasing shortage of donor organs for transplantation, there is renewed interest in marginal livers, such as those obtained from non-heart-beating donors (NHBDs) or fatty livers, particularly susceptible to ischemia/reperfusion injury.

Articles published in this issue not only help to identify new pharmacological approaches for improving liver function during ischemia/reperfusion damage, but will also stimulate the identification of molecular mediators of hepatic injury.

This special issue will become an international forum for researchers to summarize the most recent therapeutics strategies against hepatic I/R injuries.

Potential topics include, but are not limited to:

• Redox-modulating therapies
• Anti-inflammatory therapies
• Therapeutic antibodies and small molecules
• Gene therapies
• Preservation techniques
• Preconditioning
• Donor treatment